PMID- 27405295
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20181202
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 9
IP  - 1
DP  - 2016 Jul 12
TI  - Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab 
      combinations in patients with refractory/relapsed multiple myeloma.
PG  - 54
LID - 10.1186/s13045-016-0286-x [doi]
LID - 54
AB  - PURPOSE: The purpose of this study was to better understand the efficacy and 
      safety of carfilzomib, panobinostat, and elotuzumab combinations in patients with 
      refractory/relapsed multiple myeloma(R/RMM). METHODS: We retrieved and reviewed 
      published reports including carfilzomib, panobinostat, and elotuzumab combination 
      regimens for patients with R/RMM. RESULTS: We identified 20 prospective studies 
      that evaluated 2220 patients. Carfilzomib combination regimens produced an 
      overall response rate (ORR >/= PR) of 61 % in the 1211 relapsed/refractory 
      patients. At least very good partial response (VGPR) was 29 % in patients with 
      carfilzomib combinations. Finally, 49 % of the 597 patients achieved ORR in 
      patients receiving panobinostat-containing combinations. At least VGPR was 16 % 
      in patients with panobinostat combinations. Three hundred twenty-eight of these 
      449 patients (73 %) receiving elotuzumab-containing combinations achieved ORR. 
      And at least VGPR was 37 %. And, the vital nonhematologic adverse events (AEs) 
      were cardiac events and pneumonia. CONCLUSION: Carfilzomib, panobinostat, and 
      elotuzumab combination regimens produced clinical benefits in patients with 
      R/RMM.
FAU - Liu, Liping
AU  - Liu L
AD  - Department of Hematology, Weifang People's Hospital, Weifang, China.
FAU - Zhao, Ningning
AU  - Zhao N
AD  - Department of Hematology, Weifang People's Hospital, Weifang, China.
FAU - Xu, Wenjun
AU  - Xu W
AD  - Department of Hematology, Weifang People's Hospital, Weifang, China.
FAU - Sheng, Zhixin
AU  - Sheng Z
AD  - Department of Hematology, Weifang People's Hospital, Weifang, China.
FAU - Wang, Lida
AU  - Wang L
AD  - E.N.T. Department, Weifang People's Hospital, Weifang, China. 452697850@qq.com.
LA  - eng
PT  - Letter
PT  - Meta-Analysis
DEP - 20160712
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Hydroxamic Acids)
RN  - 0 (Indoles)
RN  - 0 (Oligopeptides)
RN  - 1351PE5UGS (elotuzumab)
RN  - 72X6E3J5AR (carfilzomib)
RN  - 9647FM7Y3Z (Panobinostat)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Heart Diseases/chemically induced
MH  - Humans
MH  - Hydroxamic Acids/therapeutic use
MH  - Indoles/therapeutic use
MH  - Multiple Myeloma/complications/*drug therapy
MH  - Oligopeptides/therapeutic use
MH  - Panobinostat
MH  - Pneumonia/chemically induced
MH  - Prospective Studies
MH  - Salvage Therapy/adverse effects/*methods
PMC - PMC4941034
OTO - NOTNLM
OT  - Carfilzomib
OT  - Elotuzumab
OT  - Multiple myeloma
OT  - Panobinostat
EDAT- 2016/07/14 06:00
MHDA- 2017/11/29 06:00
PMCR- 2016/07/12
CRDT- 2016/07/14 06:00
PHST- 2016/04/20 00:00 [received]
PHST- 2016/07/07 00:00 [accepted]
PHST- 2016/07/14 06:00 [entrez]
PHST- 2016/07/14 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2016/07/12 00:00 [pmc-release]
AID - 10.1186/s13045-016-0286-x [pii]
AID - 286 [pii]
AID - 10.1186/s13045-016-0286-x [doi]
PST - epublish
SO  - J Hematol Oncol. 2016 Jul 12;9(1):54. doi: 10.1186/s13045-016-0286-x.